Rocky Mountain spotted fever: what you need to know
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
27 minutes ago
- Globe and Mail
Influenza Pipeline Outlook 2025 – Clinical Trials, Treatment, ROA, Medication, MOA, Revenue Share, Companies by DelveInsight
The Influenza pipeline is experiencing unprecedented growth, driven by 120+ active players, breakthrough therapies, and recent FDA fast-track designations, signaling a transformative decade ahead in Influenza treatment. Influenza Pipeline Summary DelveInsight's Influenza Emerging Drugs report highlights innovative therapies advancing the treatment and prevention of influenza. Key candidates include Moderna's mRNA-1010, a Phase III vaccine encoding HA glycoproteins of WHO-recommended strains; SAB Biotherapeutics' SAB-176, a quadrivalent, broadly neutralizing polyclonal antibody for severe influenza; ENA Respiratory's INNA-051, an immunomodulatory intranasal spray in Phase IIa; Codagenix's CODA-VAX H1N1, a universal live-attenuated flu vaccine in Phase I; and AlloVir's ALVR106, an allogeneic, off-the-shelf VST therapy targeting multiple respiratory viruses. The report further analyzes over 120+ pipeline drugs across various clinical stages, including Phase III, II, I, preclinical, and discovery. It categorizes therapies by route of administration (oral, intravenous, intranasal, inhalation, subcutaneous, etc.), molecule type (antibodies, vaccines, peptides, proteins, immunotherapies, small molecules, stem cells), and product type (mono, combination, or both). Moderna currently leads the late-stage pipeline, showcasing the growing diversity and innovation in influenza treatment strategies. Key Takeaways from the Influenza Pipeline Report Influenza pipeline report depicts a robust space with 120+ active players working to develop 120+ pipeline therapies for Influenza treatment. In August 2025, AstraZeneca launches the first FDA-approved influenza vaccine available for self- or caregiver administration, providing a convenient, household-based option for seasonal flu vaccination. AstraZeneca launches FluMist Home, the first-of-its-kind, at-home delivery service for FLUMIST®(Influenza Vaccine Live, Intranasal). FLUMIST is the first and only seasonal influenza vaccine approved to be self-administered by adults 18 to 49 years of age or administered by a parent or caregiver to individuals 2-17 years of age. In July 2025, SK bioscience, a global innovative vaccine and biotech company dedicated to advancing human health from prevention to cure, announced that it has submitted an Investigational New Drug (IND) application to the Ministry of Food and Drug Safety (MFDS) for Phase 1/2 clinical trials of a new influenza vaccine candidate, 'NBP607B'. This candidate integrates an adjuvant into its existing cell-based influenza vaccine, 'SKYCellflu', to improve protective efficacy. SK bioscience previously applied adjuvant technology in its COVID-19 vaccine, 'SKYCovione', and now aims to extend this approach to influenza vaccines as part of its broader platform strategy. In July 2025, GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its trivalent seasonal influenza vaccines to US healthcare providers and pharmacies in preparation for the 2025-26 flu season. This immediately follows a licensing and lot-release approval from the US Food and Drug Administration (FDA). Both FLULAVAL and FLUARIX will be available in a 0.5mL, single-dose, pre-filled syringe and are indicated for people six months and older. In March 2025, Sanofi announced today the immediate adoption of influenza strains selected by the US Food and Drug Administration (FDA) to advance the manufacturing and delivery of its vaccine portfolio for the 2025-26 flu season in the US. As the world leader in flu vaccines, Sanofi had already begun its annual production of vaccines to ensure that robust supply is ready for the coming season. Strains selected by the FDA match those already used in production by the company to help protect eligible patients against flu and its potentially severe complications. In December 2024:- ModernaTX, Inc.- A Phase 3, Randomized, Observer-Blind, Active-Control Study to Evaluate the Immunogenicity, Reactogenicity, and Safety of mRNA-1083 (SARS-CoV-2 and Influenza) Vaccine in Healthy Adults ≥50 Years of Age. The purpose the study is to evaluate the immunogenicity, reactogenicity, and safety of mRNA-1083 in adults 50 years of age and older in participating countries (Japan, Taiwan, and South Korea). In November 2024:- DiaSorin Molecular LLC- The DiaSorin Molecular LIAISON® NES FLU A/B, RSV & COVID-19 real-time polymerase chain reaction (RT-PCR) assay is intended for use on the DiaSorin LIAISON® NES instrument for the in-vitro qualitative detection and differentiation of nucleic acid from influenza A, influenza B, RSV and SARS-CoV-2 virus from dry nasal swabs (NS) from human patients with signs and symptoms during the acute phase of respiratory tract infection in conjunction with clinical and epidemiological risk factors. In October 2024:- Pfizer- The purpose of this study is to learn about the safety and effects of the study vaccine for the possible prevention of influenza. Influenza is a disease that can spread easily from one person to another and cause body aches, fever, cough, and other symptoms. The study vaccine is called Pandemic Influenza modRNA (pdmFlu) Vaccine. The leading Influenza Companies such as Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., and others. Promising Influenza Therapies such as OVX836 480µg, mRNA-1010, Oseltamivir, Baloxavir, and others. Stay ahead with the most recent pipeline outlook for Influenza. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Influenza Treatment Drugs Influenza Emerging Drugs · mRNA-1010 (Moderna): A Phase III vaccine targeting WHO-recommended influenza strains (A/H1N1, A/H3N2, B/Yamagata, B/Victoria). Encodes HA glycoproteins to generate broad protection against seasonal influenza. · SAB-176 (SAB Biotherapeutics): A quadrivalent polyclonal antibody therapy developed via DiversitAb™ platform. Designed to neutralize Type A and B influenza viruses, showing broad protection potential. Targeted for severe cases and high-risk groups like elderly and immunocompromised patients. · INNA-051 (ENA Respiratory): An intranasal immunomodulatory spray in Phase IIa trials. Intended for pre- and post-exposure prophylaxis of respiratory viral infections, with potential use across multiple viruses and at-risk populations. · CODA-VAX H1N1 (Codagenix): A live-attenuated universal flu vaccine in Phase I trials. Shows promise for multi-season protection by targeting conserved viral antigens and is being developed into a quadrivalent formulation. · ALVR106 (AlloVir): An allogeneic, off-the-shelf VST therapy in preclinical development. Targets RSV, influenza, PIV, and hMPV, with in vitro data showing strong antiviral activity and potential safety benefits. Explore groundbreaking therapies and clinical trials in the Influenza Pipeline. Access DelveInsight's detailed report now! @ New Influenza Drugs Key influenza Companies: The following are the leading companies in the influenza market. These companies collectively hold the largest market share and dictate industry trends. Influenza Pipeline Drugs by Route of Administration Influenza pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration Inhalation Inhalation/Intravenous/Oral Intranasal Intravenous • Intravenous/ Subcutaneous • NA • Oral • Oral/intranasal/subcutaneous • Parenteral • Subcutaneous Influenza Pipeline Drugs by Molecule Types Influenza Products have been categorized under various Molecule types such as • Antibody • Antisense oligonucleotides • Immunotherapy • Monoclonal antibody • Peptides • Protein • Recombinant protein • Small molecule • Stem Cell • Vaccine Unveil the future of Influenza Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight's expert analysis @ Influenza Market Drivers and Barriers Scope of the Influenza Pipeline Report Coverage- Global Influenza Companies- Moderna, SAB Biotherapeutics, ENA Respiratory Pty Ltd, Codagenix, AlloVir, Osivax, CureVac AG, GlaxoSmithKline, Cocrystal Pharma Inc, Viriom, Emergent BioSolutions, Pfizer, Jiangxi Qingfeng Pharmaceutical Co. Ltd., Guangdong Raynovent Biotech Co., Ltd, FluGen Inc, BlueWillow Biologics, AVM Biotechnology LLC, Ansun Biopharma, Inc., Guangzhou Henovcom Bioscience, Sunshine Lake Pharma Co., Ltd., Emergex Vaccines, Vir Biotechnology, CSL Limited, Novavax, EMERGENT, Mitsubishi Chemical Group Corporation, Poolbeg Pharma, MYMETICS, CELLTRION INC., Avalia Immunotherapies, Meiji Holdings Co., Ltd., Clover Biopharmaceuticals, Airway Therapeutics, Inc., PrEP Biopharm, Ansun Biopharma, Cidara Therapeutics, Inc., and others. Influenza Therapies- OVX836 480µg, mRNA-1010, Oseltamivir, Baloxavir, and others Influenza Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Influenza Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III Table of Content 1. Influenza Report Introduction 2. Influenza Executive Summary 3. Influenza Overview 4. Influenza- Analytical Perspective In-depth Commercial Assessment 5. Influenza Pipeline Therapeutics 6. Influenza Late Stage Products (Phase II/III) 7. Influenza Mid Stage Products (Phase II) 8. Influenza Early Stage Products (Phase I) 9. Influenza Preclinical Stage Products 10. Influenza Therapeutics Assessment 11. Influenza Inactive Products 12. Company-University Collaborations (Licensing/Partnering) Analysis 13. Influenza Key Companies 14. Influenza Key Products 15. Influenza Unmet Needs 16 . Influenza Market Drivers and Barriers 17. Influenza Future Perspectives and Conclusion 18. Influenza Analyst Views 19. Appendix 20. About DelveInsight About DelveInsight DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Ankit Nigam Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website:
CTV News
27 minutes ago
- CTV News
Neighbours and businesses say ‘the bridge homeless shelter' in Dartmouth is posing problems
After years of fundraising for Shirley Splash pad in Dartmouth, those who helped make it a reality say they aren't able to enjoy it like they had hoped to. Massimilliano Marcelli, is a city worker and says he drives past this park every day. If him or his team notices things are a problem or need fixing like a tennis net, they pop by to fix it. But Marcelli has seen traffic in this area slow down. 'Its not as busy as it used to be, we don't see as many kids as we used to see in the playground here. Just not as many people here and we don't know what happened,' says Marcelli. Many of the families who use the splash pad are laying the blame on the doorstep of a local shelter. They're finding needles and drug paraphernalia around these parks and their neighbourhood. 'A lot of people are coming from the bridge shelter which is very close to the splash pad. That's where we assume it's coming from. We have seen active drug deals happening in the splash pad,' says Ashley LeCroy, who lives near the splash pad. The hotel turned shelter called 'the bridge' is a provincially owned homeless facility that has 178 beds. 'The Bridge is supported with $24 million annually from the Department of Opportunities and Social Development (this supports rooms, building rental, services and programming, and staff).' says Eric Parrill, in a statement from the province to CTV News. She explains the project was designed not only as a shelter but a supportive health and social intervention 'It reduces strain on emergency services, improves public safety, and helps individuals transition into stable housing,' the province says in a statement to CTV News. Former mayor of Dartmouth, Gloria McCluskey says she feels for those who are homeless but says it's also not fair to the residents who pay taxes and expect to be able to take their children to these playground but don't feel safe to do so. 'That's as good a place that we can put them. Where are we going to put the poor souls, and until we get enough housing and places for them to live, we are going to be faced with them in these situations,' says McCluskey. She was the one who was involved in the work to get the skatepark in that area put there several years ago and wants families to be able to use those spaces safely. 'Well we need more patrolling in the parks also and it shouldn't be a problem for the police alone,' says McCluskey. When it comes to security, the city says in a statement to CTV News that someone is there every morning. 'We have Mainline Needle Exchange doing daily sweeps for needles and other hazards at the splash pad, playground and surrounding area. We also have security on site from 10 a.m. to 2 p.m,' says Sarah Brannen on behalf of the city in a statement to CTV News. But locals feel that's not enough. 'I know the city has security there from ten until two because community groups and schools were showing up and being turned away because Mainline does the sweeps of all the drug drug paraphernalia and the community groups and the camps were going away,' says Jesse Sharrett, who lives near the splash pad. Sharrett feels that security should be extended for the after school crowds as well, he says at least until 7 p.m. Some businesses that are not far from the shelter say since its opened, its caused them trouble. 'Businesses are feeling the pressures of drug use and increased shelters in that area, through property crime and those sorts of complaints in that area as well,' says Tim Rissesco, Downtown Dartmouth Business commission CEO. Tim Rissesco Tim Rissesco, Downtown Dartmouth Business commission CEO. (CTV Atlantic/ Emma Convey) Rissesco explains that the businesses around Wyse Road and the shelter are not considered to be part of the downtown Dartmouth businesses although they have reached out to him with concerns. Rissessco says shops already face so much uncertainty and street issues are only adding more pressure. 'Businesses are conflicted, generally small businesses and neighours in the areas are empathetic to the people in those situations but they are also concerned for their own futures as well,' says Rissesco. 'Its very difficult for businesses and while they are trying to be kind they have a business to run and there is stealing going on and that goes with addiction and mental health issues,' adds McCuskey. The province says between May 1, 2023 and May 1, 2025, 107 people have left this shelter for housing. Including private market housing, supportive housing, or moving in with family or friends. 'The Bridge works with law enforcement, housing providers, and municipal safety teams to monitor and respond to issues in the surrounding area. In addition, security guards, staff, and peer support workers are on site around the clock to help manage and de-escalate situations as they arise,' says Parrill in her statement to CTV News Atlantic. The province says it will continue to work with service providers to support the individuals who rely on this shelter but also the surrounding community. As reported Wednesday, Halifax police say the best course of action if residents see any type of drug paraphernalia is to call 311. For more Nova Scotia news, visit our dedicated provincial page
CTV News
an hour ago
- CTV News
Albertans will have free access to COVID-19 vaccines—in B.C. if not at home
Regardless of what happens in Alberta, residents of our province will still be able to get a COVID-19 vaccination for free. Regardless of what happens in Alberta, residents of our province will still be able to get a COVID-19 vaccination for free. They just might have to hop in their vehicle to get the shot. British Columbia will continue to have a publicly funded COVID-19 vaccination program. Citing a reciprocal agreement between provinces and territories in place since 2013, B.C.'s Ministry of Health says Canadian travellers should be able to receive publicly funded immunization anywhere. And the ministry says that of course includes COVID-19 shots and of course includes Albertans. You will need identification as a resident of Canada and a personal health number or equivalent. However, the ministry says there are some caveats that can result in lengthy waits: residents of B.C. will be given priority for vaccination appointments; and locations where residents of other provinces can be vaccinated in B.C. are limited. The ministry suggests calling the Get Vaccinated call centre at 1-833-838-2323 for information on public health unit locations as well as appointment availability.
